MiNK Therapeutics Inc., a clinical-stage biopharmaceutical company, has been awarded a prestigious grant from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH). This non-dilutive funding will support the development of MiNK's allogeneic invariant natural killer T (iNKT) cell therapy platform, aimed at preventing and treating graft-versus-host disease (GvHD) following hematopoietic stem cell transplantation $(HSCT)$. The grant is a collaborative effort with the University of Wisconsin, highlighting the partnership between MiNK's iNKT manufacturing capabilities and the university's expertise in transplant immunology. This funding underscores the promise of iNKT cells in immune regulation and accelerates the development of therapies for a significant unmet medical need.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.